Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 5Phase 2 4Phase 3 3

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 42Recurrence 13Neoplasms, Plasma Cell 3Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms 1

Interventions

Dexamethasone 20Melphalan 13Thalidomide 10Bortezomib 10Lenalidomide 8Cyclophosphamide 8Prednisone 6Filgrastim 6Doxorubicin 6Vincristine 5Epoetin Alfa 5pomalidomide 3Zoledronic Acid 3Peripheral Blood Stem Cell Transplantation 3Idarubicin 3carfilzomib 2Vorinostat 2Radiotherapy 2Interferon-alpha 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Darbepoetin alfa 2Carmustine 2Calcium Dobesilate 2Busulfan 2valspodar 1sargramostim 1oblimersen 1liposomal doxorubicin 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Plasma Cell × pomalidomide × Clear all
NCT06152575 2026-05-22

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01324947 2019-11-19

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Celgene

Phase 3 Completed
74 enrolled 17 charts
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01311687 2018-10-24

NIMBUS

Celgene

Phase 3 Completed
455 enrolled 38 charts
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡